Paola Marignani PhD, MBA
Professor | Dalhousie University, Faculty of Medicine
Halifax, Canada Area, NS, CANADA
Dr. Paola Marignani is a scientist dedicated to developing personalized precision medicine that will improve human health.
Areas of Expertise (13)
Breast Cancer Research
Lung cancer Research
Gene Editing
CRISPR-Cas9
Transgenic mouse models of cancer
Cancer Metabolism
Epigenetics
Signal Trasnduction
Signalling networks
Neurodegenerative Disorders Related to Ageing
Alzheimer's Disease Spectrum
tumor suppressors and oncogenes
DNA stability and damage
Education (7)
Ivey School of Business: MBA, Executive MBA 2013
Ontario Cancer Institute: PDF, Cancer 2002
Samuel Lunenfeld Research Institute- Mount Sinai Hospital: PDF, Mass Spectrometry 2001
Harvard Division of Signal Transduction: PDF, Fellow 2000
McMaster University: PhD, Cell Biology 1997
Western University (UWO): MSc Neuropathology 1992
University of Windsor: Honours BSC, Biology and Chemistry 1988
Languages (4)
- English
- Italian
- French
- Swedish
Media Appearances (6)
House hold chemicals
Global News tv
Dr. Marignani and colleagues report on how low-dose exposure to common chemicals may contribute to the development of cancers and other diseases.
Low dose chronic exposure to chemical mixtures
CTV tv
Dr. Marignani, a member of the Halifax Project reports on how low-dose chronic exposure to common chemicals may contribute to the development of diseases.
New Drug combination halts HER2+ breast cancer in mice engineered to develop cancer
Radio Canada radio
Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked. Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
New Breast Cancer Treatment
Global News tv
Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked. Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
Promising new drugs in the battle against breast cancer
CTV tv
Promising new drugs have been discovered to be effective at halting HER2+ breast cancer in mice re-engineered to develop breast cancer. Dr. Paola Marignani and her team of scientists pre-clinically tested new drugs; AZD8055 and 2-DG. When administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked. Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
Novel drugs in the battle against breast cancer
Shedon McLeod Radio Show radio
An interview with Dr. Paola Marignani who discovered a new drug combination that stops HER2+ breast cancer from developing in mice re-engineered to develop breast cancer.
Social